We are live on ! Find out more
NVAX icon

Novavax

165 hedge funds and large institutions have $350M invested in Novavax in 2016 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 41

11% less funds holding

Funds holding: 186165 (-21)

26% less call options, than puts

Call options by funds: $9.73M | Put options by funds: $13.1M

38% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 47

78% less capital invested

Capital invested by funds: $1.59B → $350M (-$1.24B)

100% less funds holding in top 10

Funds holding in top 10: 30 (-3)

Holders
165
Holders Change
-21
Holders Change %
-11.29%
% of All Funds
4.4%
Holding in Top 10
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
New
29
Increased
59
Reduced
41
Closed
47
Calls
$9.73M
Puts
$13.1M
Net Calls
-$3.39M
Net Calls Change
+$17M

NVAX Hedge Fund Activity: Q3 2016 in Review

165 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q3 2016, worth a combined $350M — down 78% from $1.59B a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of NVAX and 29 opened new positions — a net loss of 18 holders — while 41 trimmed existing stakes and 59 added.

The largest buyer was Millennium Management, adding an estimated $35.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $151M.

  • 165 institutional investors held Novavax (NVAX) as of Q3 2016, down from 186 in Q2 2016.
  • Funds reported $350M of Novavax stock for Q3 2016, down 78% quarter-over-quarter.
  • 29 funds opened new Novavax positions in Q3 2016 and 47 closed out, a net change of -18 holders.
  • The largest Novavax buyer in Q3 2016 was Millennium Management, an estimated $35.5M added.
  • The largest Novavax seller in Q3 2016 was T. Rowe Price Associates, an estimated $151M sold.

Based on aggregated 13F filings for Q3 2016.